The Upjohn Co.

Other

Herbert G Johnson

Charles M Hall

John B Wright

Ayako Yamashita

The present invention provides certain novel substituted naphthalenes, indoles, benzofurans, and benzothiophenes of Formula I which are useful as inhibitors of leukotriene biosynthesis and as inhibitors of lipoxygenase. They are thus employed wherever it is medically necessary or desirable to inhibit these systems. ##STR1##

Substituted naphthalenes, indoles, benzofurans, and benzothiophenes as

Compounds of the formula below are useful for expanding the lumina of air passages in a mammal in need of said treatment. The compounds are also useful for treating atopic eczema and urticaria. ##STR1## wherein X and Y are the same or different and are hydrogen, fluoro, chloro, bromo, nitro, trifluoromethyl, alkyl of one to four carbon atoms, inclusive, alkoxy of one to four carbon atoms, inclusive, and cyano;

Quinoxalinones

Quinoxalinones useful for treating atopic eczema and urticaria

Compounds of the formula below are useful for expanding the lumina or air passages in a mammal in need of said treatment. The compounds are also useful for treating atopic eczema and urticaria. ##STR1## wherein X and Y are the same or different and are hydrogen, fluoro, chloro, bromo, nitro, trifluoromethyl, alkyl of one to four carbon atoms, inclusive, alkoxy of one to four carbon atoms, inclusive, and cyano;

Quinoxalinone compounds useful for expanding the lumina or air passages

Novel chemical compounds of the formula: ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, phenyl, alkali metal, or an amine cation;

DI-Tham salt of 10-cl,1,4,6,9 tetrahydro-5-methyl 4,6

This application discloses method and apparatus for solid-phase conversion of particulate metal (or swarf) into continuous metal-jacketed strip by feeding particulate metal, together with any desired reducing or alloying additives, between travelling metal jacket sheet components, the lower channel-shaped and the upper flat strip closely fitting between the channel sides; injecting air-purging reducing or inert gas to create an inside environment of protective gas rather higher than atmospheric air pressure, the gas entering the material and the embrassing jacket sheet components which after filling and closing form a permanent circumferentially and longitudinally complete jacket around the material; compacting the material in the jacket sheet components after closing by repeated compacting actions; feeding this strip forward between successive compacting actions while clear of the compacting die elements; sealing the jacket components closed together over the compacted material to form a circumferentially complete jacket; subjecting the compacted jacketed strip to a heating treatment to bring the particles and jacket to sintering and fusion-bonding temperature; returning hot gases (counterflow) to the particulate material being red in; hot-compacting the heated jacketed strip to reduce its thickness, coalesce and densify the material; and (when desired) cold-compacting the strip to improve physical properties; coil, or cut into finite lengths.

Solid-phase conversion of particulate metal into continuous strip

An improved dosage regimen for the administration of the pharmacologically acceptable salts or esters of a compound of the formula: ##STR1## wherein X and Y can be the same or different and are selected from the group consisting of hydrogen, alkyl of from one to six carbon atoms, inclusive, cycloalkyl of five or six carbon atoms, inclusive, phenyl, hydroxyl, alkoxy having from one to three carbon atoms, inclusive, halogen, trifluoromethyl, cyano, carboxyamide and --CO.sub.2 H; Z is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, and phenyl and provided when X is chloro at least one of Y and Z are other than hydrogen consisting of the initial administration of a priming dose (high) and thereafter administering a maintenance (low) dose of from 1/5th to 1/1000th of the priming dose, the maintenance doses being continually administered every 4 to 12 hours or as needed. The priming dose is re-administered followed by the maintenance doses whenever a 48 hour period without dosage administration occurs.

Dosage regimen

A dosing schedule for Disodiumcromoglycate and Disodiumcromoglycate biologues whereby a substantially smaller dosage is required to bring about effective allergy inhibition. Compositions are also provided.

Dosage schedule

Novel compounds of (I) ##STR1## are useful in the prophylactic treatment of sensitized humans and animals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature. The compounds are formulated with pharmaceutical carriers for oral, parenteral, inhalation or rectal means of administration.

Compounds, compositions and methods of use

Novel compounds of formula 1 ##SPC1## And ##SPC2## Are useful in the prophylactic treatment of sensitized humans and animals for allergy and all anaphylactic reactions of a reagin or non-reagin mediated nature. The compounds are formulated with pharmaceutical carriers for oral, parenteral, inhalation or rectal means of administration.

Pyridine dioxamic acids and esters

Novel chemical compounds of the formula: ##SPC1## Wherein

Growing community of inventors

Kalamazoo, MI, United States of America

Herbert G Johnson